JP2022553653A5 - - Google Patents

Info

Publication number
JP2022553653A5
JP2022553653A5 JP2022521684A JP2022521684A JP2022553653A5 JP 2022553653 A5 JP2022553653 A5 JP 2022553653A5 JP 2022521684 A JP2022521684 A JP 2022521684A JP 2022521684 A JP2022521684 A JP 2022521684A JP 2022553653 A5 JP2022553653 A5 JP 2022553653A5
Authority
JP
Japan
Prior art keywords
formulation according
weight
highly lipophilic
physiologically active
cannabinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022521684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553653A (ja
JP7778069B2 (ja
Filing date
Publication date
Priority claimed from EP19203580.6A external-priority patent/EP3808341A1/de
Application filed filed Critical
Publication of JP2022553653A publication Critical patent/JP2022553653A/ja
Publication of JP2022553653A5 publication Critical patent/JP2022553653A5/ja
Priority to JP2025169943A priority Critical patent/JP2025182116A/ja
Application granted granted Critical
Publication of JP7778069B2 publication Critical patent/JP7778069B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022521684A 2019-10-16 2020-10-16 高親油性生理活性物質の放出制御製剤 Active JP7778069B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025169943A JP2025182116A (ja) 2019-10-16 2025-10-08 高親油性生理活性物質の放出制御製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19203580.6A EP3808341A1 (de) 2019-10-16 2019-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
EP19203580.6 2019-10-16
PCT/EP2020/079248 WO2021074403A1 (de) 2019-10-16 2020-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025169943A Division JP2025182116A (ja) 2019-10-16 2025-10-08 高親油性生理活性物質の放出制御製剤

Publications (3)

Publication Number Publication Date
JP2022553653A JP2022553653A (ja) 2022-12-26
JP2022553653A5 true JP2022553653A5 (https=) 2023-10-19
JP7778069B2 JP7778069B2 (ja) 2025-12-01

Family

ID=68281185

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022521684A Active JP7778069B2 (ja) 2019-10-16 2020-10-16 高親油性生理活性物質の放出制御製剤
JP2025169943A Pending JP2025182116A (ja) 2019-10-16 2025-10-08 高親油性生理活性物質の放出制御製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025169943A Pending JP2025182116A (ja) 2019-10-16 2025-10-08 高親油性生理活性物質の放出制御製剤

Country Status (10)

Country Link
US (1) US20240139215A1 (https=)
EP (2) EP3808341A1 (https=)
JP (2) JP7778069B2 (https=)
CN (1) CN114945353A (https=)
AU (1) AU2020365443A1 (https=)
BR (1) BR112022006643A2 (https=)
CA (1) CA3157654A1 (https=)
IL (1) IL292018A (https=)
MX (1) MX2022004523A (https=)
WO (1) WO2021074403A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3808336A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
CA3205594A1 (en) 2020-12-17 2022-06-23 Nalu Bio, Inc. Synthesis of cannabidiol and analogs thereof, and related compounds, formulations, and methods of use
GB2618322A (en) * 2022-04-29 2023-11-08 113 Botanicals Ltd Compositions and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
EP1364646A4 (en) 2001-03-01 2005-08-03 Grelan Pharmaceutical Co FENOFIBRATE CONTAINING COMPOSITION
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
CA2929321C (en) 2013-10-29 2022-04-05 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
DE102014213548A1 (de) * 2014-07-11 2016-01-14 Hans Brammer Cannabispräparat
RS67855B1 (sr) * 2014-08-11 2026-03-31 Woerwag Pharma Gmbh & Co Kg Formulacija koja sadrži čestice
IL246790A0 (en) 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
WO2018035030A1 (en) 2016-08-15 2018-02-22 Corr-Jensen Inc. Time release fat-soluble actives
JP2019137614A (ja) 2018-02-06 2019-08-22 富士フイルム株式会社 経口用医薬組成物及びその製造方法
DE102019100483A1 (de) * 2019-01-10 2020-07-16 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm

Similar Documents

Publication Publication Date Title
JP2022553653A5 (https=)
ME01944B (me) Farmaceutske kompozicije koje sadrže rozuvastatin kalcijum
JP2025182116A5 (https=)
JP2005511641A (ja) ショウガ抽出物製剤
EP4115896A1 (fr) Extrait de plante très concentré en safranal, procédé d'obtention et utilisations
JP6641062B2 (ja) テコビリマットの経口用医薬組成物及びその調製法
CN110833531B (zh) 一种维生素e制剂及其制备方法
JP2025182116A (ja) 高親油性生理活性物質の放出制御製剤
EP1994926B9 (en) Valsartan formulations
CN103385876B (zh) 一种夫罗曲坦的药物组合物及其制备方法
KR102349893B1 (ko) 제약 투여 형태
JPWO2019004449A1 (ja) 医薬組成物
JP2022553652A5 (https=)
Bala et al. Natural gums and mucilage as matrix formers in sustained released dosage forms
JP2020525424A (ja) テルミナリア・アルジュナの樹皮からのアルジュングルコシドの標準化組成物の調製のための方法
JP2009501214A (ja) クロピドグレルビスルファートを含有する薬学的組成物
JP5698395B2 (ja) 結晶及び該結晶を含有してなる医薬製剤
Al-Pokhiti et al. Development and evaluation of sustained release matrix tablets of ketoprofen employing natural polymers (pomegranate peel and acacia powders)
CN107137384A (zh) 紫草素在制备治疗肺癌药物中的应用
CN115715764B (zh) 一种阿帕替尼口腔贴片及其制备方法
CA2259730A1 (en) Sustained release tablets containing bupropion hydrochloride
KR102760108B1 (ko) 수용해도와 투과도를 향상시켜 생체이용률이 개선된 무정형 아픽사반 고체분산체 제제 및 그의 서방성 정제
CN101222929A (zh) 银杏提取物
AU2020366134B2 (en) Controlled release formulations of highly lipophilic physiologically active substances
Reddy et al. Conception and Evaluation of Gemfibrozil as Immediate Drug Delivery System